CRMD
CorMedix Inc.
Biotechnology · Healthcare · United States
7.64
close · 2026-10-29
value
84
cheaper than peers84
quality
95
stronger fundamentals95
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.45× | 95 |
| price to book | 1.29× | 82 |
| EV to EBITDA | 2.07× | 76 |
| forward P/E | 21.83× | 47 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 42.1% | 96 |
| return on equity | 54.9% | 96 |
| revenue growth | 156.5% | 82 |
| debt to equity | 32.0% | 38 |
4 of 4 measures available
Facts
| market cap | $595M |
| free cash flow | $178.1M |
| employees | 191 |
| first trade | 2010-05-13 |
| next earnings | 2026-08-13 |
| fundamentals updated | 2026-09-02 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 2.04 | -0.30 | -0.91 | -0.74 |
| free cash flow | $172.8M | -$50.7M | -$38.7M | -$24.6M |
| net income | $163.1M | -$17.9M | -$46.3M | -$29.7M |
| revenue | $311.7M | $43.5M | $0 | $65,408 |
| unusual items | -$1.2M | -$31,000 | -$28,994 | $37,145 |